Clinical evaluation of Mamajjaka ghanavati in the management of Madhumeha(Type II Diabetes mellitus) - MGV

Central Council of Research in Ayurvedic Sciences0 个研究点目标入组 180 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Diabetics aged between 35 to 65 years.
•2.Patients who are diagnosed to be Type II Diabetics by having Glycosylated Haemoglobin (HbA1c) between 6.5% - 9% or BS-F between 126 mg% - 200 mg% or BS-PP / Random between 200 mg% - 250 mg%.
•3. Willing to participate and able to provide signed informed consent.

•1. Patients suffering from the complications of Diabetes Mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.
•2. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•3.Hypertensive patients ( > 140 / 90 mm Hg).
•Symptomatic patient with clinical evidence of Heart failure.
•4.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2 mg/dl),uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
•5. Pregnant / Lactating women.
•6. Patient on steroids, oral contraceptive pills or estrogens replacement therapy.
•7. Alcoholics and/or drug abusers.
•8.Patients with evidence of malignancy
•9.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•10.H/o hypersensitivity to any of the trial drugs or their ingredients.
•11.Patients who have completed participation in any other clinical trial during the past six (06) months.
•12.Any other condition which the Investigator thinks may jeopardize the study.

发起方

Central Council of Research in Ayurvedic Sciences